Claire Reiss Net Worth

The estimated Net Worth of Claire Reiss is at least $455 mil dollars as of 19 October 2016. Claire Reiss owns over 227,272 units of Biocept Inc stock worth over $455,172 and over the last 11 years Claire sold BIOC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Claire Reiss BIOC stock SEC Form 4 insiders trading

Claire has made over 2 trades of the Biocept Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Claire bought 227,272 units of BIOC stock worth $249,999 on 19 October 2016.

The largest trade Claire's ever made was buying 614,273 units of Biocept Inc stock on 4 May 2016 worth over $614,273. On average, Claire trades about 280,515 units every 56 days since 2014. As of 19 October 2016 Claire still owns at least 1,046,613 units of Biocept Inc stock.

You can see the complete history of Claire Reiss stock trades at the bottom of the page.

What's Claire Reiss's mailing address?

Claire's mailing address filed with the SEC is 5810 Nancy Ridge Dr # 150, San Diego, CA 92121, USA.

Insiders trading at Biocept Inc

Over the last 11 years, insiders at Biocept Inc have traded over $2,456 worth of Biocept Inc stock and bought 1,703,300 units worth $1,869,312 . The most active insiders traders include Claire Reiss, Edward A. Neff y David F Hale. On average, Biocept Inc executives and independent directors trade stock every 92 days with the average trade being worth of $27,462. The most recent stock trade was executed by David F Hale on 9 December 2021, trading 445 units of BIOC stock currently worth $1,807.

What does Biocept Inc do?

biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar

Complete history of Claire Reiss stock trades at Biocept Inc

Biocept Inc executives and stock owners

Biocept Inc executives and other stock owners filed with the SEC include:

• Michael Nall,
  President, Chief Executive Officer, Director
• Timothy Kennedy,
  Chief Financial Officer, Senior Vice President - Operations, Corporate Secretary
• Michael Terry,
  Sr. VP of Corp. Devel.
• Lyle Arnold,
  Senior Vice President - Research & Development, Chief Scientific Officer
• David Hale,
  Non-Executive Chairman of the Board
• Samuel D. Riccitelli,
  Interim Pres & CEO and Independent Chairman
• Margaret Faye Wilson,
  Lead Independent Director
• Ivor Royston,
  Independent Director
• Bruce Huebner,
  Independent Director
• Bruce Gerhardt,
  Independent Director
• Marsha Chandler,
  Independent Director
• Samuel Riccitelli,
  Director
• Michael Terry,
  Senior Vice President - Corporate Development
• Cory Dunn,
  Senior Vice President of Commercial Operations
• Antonio Paternostro,
  VP of Sales
• Dr. Philippe J. Marchand Ph.D.,
  Chief Operating Officer
• Dr. Michael C. Dugan M.D.,
  Sr. VP, Chief Medical Officer & Medical Director
• Dr. Veena M. Singh,
  Sr. Medical Director
• David S. Moskowitz R.Ph., MBA,
  VP of Strategy & Corp. Communications
• Darrell Taylor Esq.,
  Sr. VP, Chief Legal Officer & Chief Compliance Officer
• Dr. Lyle J. Arnold Ph.D.,
  Chief Scientist & Member of Scientific Advisory Board
• Pavel Tsinberg,
  Director of Technology Devel.
• Antonino Morales,
  Interim CFO & Director
• Dr. Soon Kap Hahn Ph.D.,
  Founder
• Quyen Thi Dao Haddock,
  Director
• Bridge Lb Healthcare Master...,
  
• Edward A. Neff,
  Director
• Veena Singh,
  Sr VP & Sr Med Director
• Claire Reiss,
  10% owner
• Linda M Rubinstein,
  Director
• Raaj Trivedi,
  VP, COMMERCIAL OPERATIONS
• Mark G Foletta,
  Interim CFO
• Philippe Marchand,
  Chief Operations Officer
• William G Kachioff,
  SVP, CFO AND SECRETARY
• Farideh Z. Bischoff,
  VICE PRESIDENT
• Darrell Taylor,
  See remarks
• Michael C Dugan,
  Chief Med Off & Med. Director
• Antonino Morales,
  Interim CFO